Tech Company Financing Transactions
Ambys Medicines Funding Round
Ambys Medicines, based in San Francisco, scored $140 million from Takeda Ventures and Third Rock Ventures.
Transaction Overview
Company Name
Announced On
8/10/2018
Transaction Type
Venture Equity
Amount
$140,000,000
Round
Series A
Investors
Takeda Ventures (Asit Parikh)
Third Rock Ventures (Charles Homcy)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
131 Oyster Point Blvd. 200
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Ambys Medicines is working to fundamentally transform the lives of people suffering from severe liver diseases by creating breakthrough therapies capable of restoring liver function, preventing the progression of liver disease, and treating the devastating complications of liver failure.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffrey Jonker
Chief Medical Officer
Glenn Pierce
Chief Scientific Officer
Michael Holmes
Controller
Ran Xiao
Vice President
Stanley Hollenbach
VP - Bus. Development
Deidre Roniger
VP - Human Resources
Amanda Valentino
Browse more venture capital transactions:
Prev: 8/10/2018: OfferUp venture capital transaction
Next: 8/10/2018: Akili Interactive venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We record funding rounds that are announced publicly. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs